Julio Font
Directeur Général chez Noray Bioinformatics SL
Profil
Julio Font is the founder and former Chief Executive Officer of Noray Bioinformatics SL, a company he founded in 2002.
He is currently the Chief Executive Officer of Histocell SL.
Postes actifs de Julio Font
| Sociétés | Poste | Début |
|---|---|---|
Noray Bioinformatics SL
 Noray Bioinformatics SL Packaged SoftwareTechnology Services Noray Bioinformatics SL develops software products for the biosciences sector. It offers support to the biosciences sector: Biotechnology, Biomedicine, and Bipharmacy. The company was founded by Julio Font in 2002 and is headquartered in Derio, Spain. | Directeur Général | 21/10/2002 |
Histocell SL
 Histocell SL BiotechnologyHealth Technology Histocell SL manufactures and develops cell therapy drugs. The firm specializes in the development of cell therapy drugs that treat conditions such as spinal cord injuries, idiopathic pulmonary fibrosis, scar tissue defects, and dermo-epidermal deficiencies. Its service portfolio encompasses cell therapy services for clinical applications, molecular and cellular biology analysis, biocompatibility tests, and biological research. The company was founded in 2004 and is headquartered in Derio, Spain. | Directeur Général | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Noray Bioinformatics SL
Noray Bioinformatics SL Packaged SoftwareTechnology Services Noray Bioinformatics SL develops software products for the biosciences sector. It offers support to the biosciences sector: Biotechnology, Biomedicine, and Bipharmacy. The company was founded by Julio Font in 2002 and is headquartered in Derio, Spain. | Technology Services |
Histocell SL
Histocell SL BiotechnologyHealth Technology Histocell SL manufactures and develops cell therapy drugs. The firm specializes in the development of cell therapy drugs that treat conditions such as spinal cord injuries, idiopathic pulmonary fibrosis, scar tissue defects, and dermo-epidermal deficiencies. Its service portfolio encompasses cell therapy services for clinical applications, molecular and cellular biology analysis, biocompatibility tests, and biological research. The company was founded in 2004 and is headquartered in Derio, Spain. | Health Technology |
